筛选与评估减缓肠道发炎功效之益生菌
Screening and Evaluation of Probiotics for Reducing Intestinal Inflammation
DOI: 10.12677/HJFNS.2022.111006, PDF,  被引量   
作者: 陈雅君, 王启宪, 蔡侑珊, 林诗伟, 陈炎炼：生物工程中心，葡萄王生技股份有限公司，台湾 桃园；吴文歆：上海葡萄王企业有限公司，上海；陈劲初：台湾大学食品科技研究所，台湾 台北；实践大学食品营养与保健生技学系，台湾 台北；中原大学生物科技学系，台湾 桃园
关键词: 乳酸片球菌Pediococcus acidilactici GKA4；戊醣片球菌Pediococcus pentosaceus GKP4；肠道发炎； 葡聚糖硫酸；益生菌；肠胃道保护； Pediococcus acidilactici GKA4； Pediococcus pentosaceus GKP4； Intestinal Inflammation； Dextran Sulfate Sodium (DSS)； Probiotics； Gastrointestinal Tract Protection
摘要: 本篇利用葡聚糖硫酸(Dextran Sulfate Sodium, DSS)诱发小鼠肠道发炎的模式来筛选与评估益生菌在减缓肠道发炎与损伤的效果。实验将8周龄的BALB/c小鼠分为六组(n = 10)：正常对照组(无DSS诱导)、负对照组(DSS诱导)、片球菌GKA4组(DSS + GKA4)、片球菌GKP4组(DSS + GKP4)、乳酸菌GKR1组(DSS + GKR1)、以及乳酸菌GK4组(DSS + GK4)。连续14天以相当于成人一天摄取1克的剂量管喂小鼠益生菌，并于第7天到第14天的饮水中加入3.5% DSS，藉以诱发肠道发炎。实验结果显示给予3.5% DSS后，片球菌GKA4组及GKP4组与负对照组相比下，其对于体重减轻、结肠长度、疾病活动指数等指标均有明显改善。此外，亦可降低血清中促炎细胞激素IL-1β、IL-6及TNF-α含量，藉此减缓由DSS引发的肠道发炎反应。综观上述结果，片球菌P. acidilactici GKA4与P. pentosaceus GKP4具有应用于肠道保护的益生菌潜力。
Abstract: In this study, we applied Dextran Sulfate Sodium (DSS)-induced enteritis in mice to evaluate the effects of probiotics on reducing intestinal inflammation and damage. The 8-week-old BALB/c mice were divided into six groups (n = 10): normal group (without DSS), negative control group (DSS-induced), probiotic Pediococcus acidilactici GKA4 group (DSS + GKA4), Pediococcus pentosaceus GKP4 group (DSS + GKP4), Lactobacillus reuteri GKR1 group (DSS + GKR1), and GK4 group (DSS + GK4). Mice were given tested bacteria at an equivalent to 1 gram of adult daily intake for 14 consecutive days. Then 3.5% DSS was added to drinking water from day 7th to day 14th to induce intestinal damage. The results showed that the Pediococcus GKA4 group and GKP4 group were significantly improved in weight loss, colon length, disease activity index, and other indicators when compared with the negative control group. In addition, both Pediococcus groups reduced the levels of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in serum; thereby, alleviating the intestinal inflammation caused by DSS. Based on these results, P. acidilactici GKA4 and P. pentosaceus GKP4 have the potential characteristic to be used as probiotics for intestinal-related diseases.
文章引用：陈雅君, 王启宪, 蔡侑珊, 林诗伟, 吴文歆, 陈炎炼, 陈劲初. 筛选与评估减缓肠道发炎功效之益生菌[J]. 食品与营养科学, 2022, 11(1): 44-55. https://doi.org/10.12677/HJFNS.2022.111006

参考文献

[1] Serban, D.E. (2015) Microbiota in Inflammatory Bowel Disease Pathogenesis and Therapy: Is It All About Diet? Nutri-tion in Clinical Practice, 30, 760-779. [Google Scholar] [CrossRef] [PubMed]
[2] Ramos, G.P. and Papadakis, K.A. (2019) Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clinic Proceedings, 94, 155-165. [Google Scholar] [CrossRef] [PubMed]
[3] Yen, H.H., Weng, M.T., Tung, C.C., Wang, Y.T., Chang, Y.T., Chang, C.H., Shieh, M.J., Wong, J.M. and Wei, S.C. (2019) Epidemiological Trend in Inflammatory Bowel Disease in Taiwan from 2001 to 2015: A Nationwide Population-Based Study. Intestinal Research, 17, 54-62. [Google Scholar] [CrossRef] [PubMed]
[4] Kaplan, G.G. (2015) The Global Burden of IBD: From 2015 to 2025. Nature Reviews Gastroenterology & Hepatology, 12, 720-727. [Google Scholar] [CrossRef] [PubMed]
[5] Kostic, A.D., Xavier, R.J. and Gevers, D. (2014) The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead. The Journal of Gastroenterology, 146, 1489-1499. [Google Scholar] [CrossRef] [PubMed]
[6] Aldars-García, L., Marin, A.C., Chaparro, M. and Gisbert, J.P. (2021) The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review. In-ternational Journal of Molecular Sciences, 22, 3076. [Google Scholar] [CrossRef] [PubMed]
[7] Sheil, B., Shanahan, F. and O’Mahony, L. (2007) Probiotic Effects on Inflammatory Bowel Disease. The Journal of Nutrition, 137, 819S-824S. [Google Scholar] [CrossRef] 
[8] Dunne, C., Murphy, L., Flynn, S., O’Mahony, L., O’Halloran, S., Feeney, M., Morrissey, D., Thornton, G., Fitzgerald, G., Daly, C., Kiely, B., Quigley, E.M., O’Sullivan, G.C., Shanahan, F. and Collins, J.K. (1999) Probiotics: From Myth to Reality. Demonstration of Functionality in Animal Models of Dis-ease and in Human Clinical Trials. Antonie Van Leeuwenhoek, 76, 279-292. [Google Scholar] [CrossRef] 
[9] Borchers, A.T., Selmi, C., Meyers, FJ, Keen, C.L. and Gershwin, M.E. (2009) Probiotics and Immunity. Journal of Gastroenterology, 44, 26-46. [Google Scholar] [CrossRef] [PubMed]
[10] Gao, J., Li, Y., Wan, Y., Hu, T., Liu, L., Yang, S., Gong, Z., Zeng, Q., Wei, Y., Yang, W., Zeng, Z., He, X., Huang, S.H. and Cao, H. (2019) A Novel Postbiotic from Lactobacillus rhamnosus GG with a Beneficial Effect on Intestinal Barrier Function. Frontier in Microbiology, 10, Article No. 477. [Google Scholar] [CrossRef] [PubMed]
[11] Qiao, Y., Qiu, Z., Tian, F., Yu, L., Zhao, J., Zhang, H., Zhai, Q. and Chen, W. (2021) Pediococcus acidilactici Strains Improve Constipation Symptoms and Regulate Intestinal Flora in Mice. Frontiers in Cellular and Infection Microbiology, 11, Article ID: 655258. [Google Scholar] [CrossRef] [PubMed]
[12] Umu, Ö.C., Bäuerl, C., Oostindjer, M., Pope, P.B., Hernández, P.E., Pérez-Martínez, G. and Diep, D.B. (2016) Thepotential of Class II Bacteriocins to Modify Gut Microbiota to Im-prove Host Health. PLoS ONE, 11, e0164036. [Google Scholar] [CrossRef] [PubMed]
[13] Zommiti, M., Bouffartigues, E., Maillot, O., Barreau, M., Szunerits, S., Sebei, K., Feuilloley, M., Connil, N. and Ferchichi, M. (2018) In Vitro Assessment of the Probiotic Prop-erties and Bacteriocinogenic Potential of Pediococcus pentosaceus MZF16 Isolated from Artisanal Tunisianmeat “Dried Ossban”. Frontiers in Microbiology, 9, Article No. 2607. [Google Scholar] [CrossRef] [PubMed]
[14] Perše, M. and Cerar, A. (2012) Dextran Sodium Sulphate Colitis Mouse Model: Traps and Tricks. Journal of Biomedicine and Biotechnology, 2012, Article ID: 718617. [Google Scholar] [CrossRef] [PubMed]
[15] Eichele, D.D. and Kharbanda, K.K. (2017) Dextran Sodium Sulfate Coli-tis Murine Model: An Indispensable Tool for Advancing Our Understanding of Inflammatory Bowel Diseases Patho-genesis. World Journal of Gastroenterology, 23, 6016-6029. [Google Scholar] [CrossRef] [PubMed]
[16] Wirtz, S., Neufert, C., Weigmann, B. and Neurath, M.F. (2007) Chemically Induced Mouse Models of Intestinal Inflammation. Nature Protocols, 2, 541-546. [Google Scholar] [CrossRef] [PubMed]
[17] Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y. and Nakaya, R. (1990) A Novel Method in the Induction of Reliable Experimental Acute and Chronic Ulcerative Colitis in Mice. Gastroenterology, 98, 694-702. [Google Scholar] [CrossRef] 
[18] Mizoguchi, E., Low, D., Ezaki, Y. and Okada, T. (2020) Re-cent Updates on the Basic Mechanisms and Pathogenesis of Inflammatory Bowel Diseases in Experimental Animal Models. Intestinal Research, 18, 151-167. [Google Scholar] [CrossRef] [PubMed]
[19] Chassaing, B., Aitken, J. D., Malleshappa, M. and Vijay-Kumar, M. (2014) Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice. Current Protocols in Immunology, 104, 15.25.1-15.25.14. [Google Scholar] [CrossRef] [PubMed]
[20] Zhang, Y., Zhao, X., Zhu, Y., Ma, J., Ma, H. and Zhang, H. (2018) Probiotic Mixture Protects Dextran Sulfate Sodium-Induced Colitis by Altering Tight Junction Protein Expres-sions and Increasing Tregs. Mediators of Inflammation, 2018, Article ID: 9416391. [Google Scholar] [CrossRef] [PubMed]
[21] Yen, H.H., Weng, M.T., Tung, C.C., Wang, Y.T., Chang, Y.T., Chang, C.H., Shieh, M.J., Wong, J.M. and Wei, S.C. (2019) Epidemiological Trend in Inflammatory Bowel Disease in Taiwan from 2001 to 2015: A Nationwide Population-Based Study. Intestinal Research, 17, 54-62. [Google Scholar] [CrossRef] [PubMed]
[22] Ng, S.C., Shi, H.Y., Hamidi, N., Underwood, F.E., Tang, W., Benchimol, E.I., Panaccione, R., Ghosh, S., Wu, J.C.Y., Chan, F.K.L., Sung, J.J.Y. and Kaplan, G.G. (2017) Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies. The Lancet, 390, 2769-2778. [Google Scholar] [CrossRef] 
[23] Ng, W.K., Wong, S.H. and Ng, S.C. (2016) Changing Epi-demiological Trends of Inflammatory Bowel Disease in Asia. Intestinal Research, 14, 111-119. [Google Scholar] [CrossRef] [PubMed]
[24] Wong, M.C., Ding, H., Wang, J., Chan, P.S. and Huang, J. (2019) Prevalence and Risk Factors of Colorectal Cancer in Asia. Intestinal Research, 17, 317-329. [Google Scholar] [CrossRef] [PubMed]
[25] Lewis, J.D. and Abreu, M.T. (2017) Diet as a Trigger or Therapy for Inflammatory Bowel Diseases. The Journal of Gastroenterology, 152, 398-414. [Google Scholar] [CrossRef] [PubMed]
[26] Lichtenstein, G.R., Loftus, E.V., Isaacs, K.L., Regueiro, M.D., Gerson, L.B. and Sands, B.E. (2018) ACG Clinical Guideline: Management of Crohn’s Disease in Adults. The American Journal of Gastroenterology, 113, 481-517. [Google Scholar] [CrossRef] [PubMed]
[27] Shafiee, N.H., Manaf, Z.A., Mokhtar, N.M. and Raja Ali, R.A. (2021) Anti-Inflammatory Diet and Inflammatory Bowel Disease: What Clinicians and Patients Should Know? Intestinal Re-search, 19, 171-185. [Google Scholar] [CrossRef] [PubMed]
[28] Kruis, W., Fric, P., Pokrotnieks, J., Lukás, M., Fixa, B., Kascák, M., Kamm, M.A., Weismueller, J., Beglinger, C., Stolte, M., Wolff, C. and Schulze, J. (2004) Maintaining Remission of Ul-cerative Colitis with the Probiotic Escherichia coli Nissle 1917 Is as Effective as with Standard Mesalazine. Gut, 53, 1617-1623. [Google Scholar] [CrossRef] [PubMed]
[29] Fujiya, M., Ueno, N. and Kohgo, Y. (2014) Probiotic Treatments for Induction and Maintenance of Remission in Inflammatory Bowel Diseases: A Meta-Analysis of Randomized Controlled Trials. Clinical Journal of Gastroenterology, 7, 1-13. [Google Scholar] [CrossRef] [PubMed]
[30] Mitselou, A., Grammeniatis, V., Varouktsi, A., Papadatos, S.S., Katsanos, K. and Galani, V. (2020) Proinflammatory Cytokines in Ir-ritable Bowel Syndrome: A Comparison with Inflammatory Bowel Disease. Intestinal Research, 18, 115-120. [Google Scholar] [CrossRef] [PubMed]
[31] Wang, L., Walia, B., Evans, J., Gewirtz, A.T., Merlin, D. and Sitaraman, S.V. (2003) IL-6 Induces NF-kappa B Activation in the Intestinal Epithelia. The Journal of Immunology, 171, 3194-3201. [Google Scholar] [CrossRef] [PubMed]